|
Patent landscape, scope, and claims summary: |
United States Patent 7,713,930 Patent Landscape Analysis: Claims, Scope, Expiration, and US Litigation/Entry Risks
United States Patent 7,713,930 (US7731930) defines a US claim set that is time-limited by statutory expiration and tied to its priority/filing history. The patent landscape around US7731930 typically includes: (i) continuation and related “family” patents that cover adjacent claim scope (process, compositions, or dependent variants), (ii) formulation or method-of-use continuations that can extend practical exclusivity against specific dosage forms or indications, and (iii) later-design-around patents that pursue different structures, process parameters, or therapeutic labeling positions. A critical evaluation requires mapping independent and dependent claim elements to how competitors practice, then checking whether later patents or other exclusivity regimes (Orange Book, Hatch-Waxman, or biologic exclusivity) create additional barriers.
However, a complete, accurate, and claim-by-claim analysis of US7731930’s scope, plus a verified landscape of citing/patent family members, is not possible from the information provided in this request alone.
What is US Patent 7,713,930 actually claiming and how broad are the independent claims?
A complete claim construction and scope assessment requires the exact claim text of US7731930 (independent claims and their limitations) and the specification definitions used by the patentee. Without the claim language, the analysis cannot identify:
- the precise structural or functional limitations that control infringement,
- the “critical” terms that narrow or broaden scope,
- whether claim scope is composition-based, process-based, or method-of-use based,
- whether dependent claims introduce additional mandatory limitations that materially change infringement risk,
- and whether the claims are susceptible to design-around by altering a single element (e.g., excipient selection, process condition, dosage form architecture, sequence variant, or dosing schedule).
How do dependent claims narrow US7731930 and what design-around options do they imply?
Dependent-claim narrowing can turn a seemingly broad independent claim into a narrow commercial right. The landscape impact depends on whether dependent claims add:
- specific ranges (temperature, pH, pressure, residence time, particle size),
- specific ingredients/excipients or carrier matrices,
- specific genetic/biological constructs or engineered sequence constraints,
- specific administration regimens or patient selection criteria,
- or specific device/packaging constraints.
Those determinations require the actual dependent claim language.
Does US7731930 claim a composition, a process, or a method of treatment?
US7731930 must be classified to understand its likely competitors and enforcement targets (e.g., ANDA formulation carveouts versus biogeneric process/construct barriers). That classification also requires the claim and title/abstract.
Which patent family members exist for US 7,713,930 and do they expand or contract claim scope?
Patent landscapes for a single issued US patent typically include the “same invention” family and near-neighbor continuations. Family mapping needs:
- priority application number(s),
- publication numbers (US and WO),
- and the status of related continuation/divisional claims.
Without those bibliographic details and family documents, the analysis cannot provide:
- a verified list of related US patents,
- issuance/expiration dates per member,
- territorial coverage, or
- which family members are more enforceable (e.g., those with later priority but closer-to-market claim scope).
How many continuation patents reference or follow from US 7,713,930?
This requires citation and family datasets. The number, filing dates, and claim evolution cannot be generated accurately without the underlying record.
When does US Patent 7,713,930 expire in the US and what exclusivity can it still block?
Timelines must be calculated using:
- earliest effective filing date,
- term adjustments (PTA),
- patent term extension (PTE) if applicable,
- and any terminal disclaimer.
Without the bibliographic data for filing and any PTA/PTE indicators, the expiration date cannot be stated correctly.
What is the PTA/PTE-adjusted expiration date for US7731930?
PTA and PTE materially affect enforcement windows against generic entry. The adjusted date requires USPTO assignment and file history records tied to the patent.
What regulatory exclusivity (Orange Book or other regimes) overlaps with US7731930?
Overlap depends on whether the drug is small molecule, biologic, and whether the patent is listed in FDA’s Orange Book for a specific NDA/ANDA product. That requires:
- the FDA product mapping, and
- the specific Orange Book patent listing(s) tied to US7731930.
No drug association was provided with the request.
What patents are most closely related to US 7,713,930 based on citations and claim overlap?
A critical landscape analysis uses:
- forward citations (what patents cite US7731930 and likely compete on the same concept),
- backward citations (what was already disclosed that narrowed the novelty of US7731930),
- and patent claim similarity clustering.
This cannot be reliably performed without access to the USPTO or lens-level citation dataset for US7731930.
Which later US patents cite US7731930 and could be leveraged for follow-on enforcement?
Answering this requires listing the citing patents, assignees, filing dates, and what claim elements they pursue.
What prior art was used against US7731930 and how does that affect enforceability?
Assessing risk requires knowing:
- whether novelty was challenged by specific references,
- the prosecution outcomes (amendments and arguments),
- and whether any claims were narrowed during examination.
That requires file history details or at least the issued claim language plus the prosecution narrative.
How strong is the patent estate for US 7,713,930 against generic entry?
Strength is not just “issued claim breadth.” It depends on enforceability signals:
- whether claims were allowed after narrowing amendments,
- whether the claims cover core commercial practice or edge variations,
- whether the claim elements are easy to design around,
- and whether the patent is listed for the approved drug product or only for narrower variants.
Without claim text and the related regulatory product mapping, no credible strength assessment can be delivered.
What generic entry risks exist for the commercial product potentially covered by US7731930?
Risks are different for:
- process patents (harder under method-of-use labeling differences but easier for generic “same process” infringement),
- formulation patents (often contested in ANDA challenges),
- method-of-use patents (label carveouts can avoid infringement),
- and device/system claims (often blocked by design and manufacturing differences).
This requires the drug identity and the patent claim type.
What patent litigation involves US 7,713,930, including Paragraph IV and Hatch-Waxman cases?
A verified litigation landscape needs:
- case captions,
- district courts and docket numbers,
- parties,
- asserted claims (which claim numbers),
- outcomes (dismissal, settlement, stipulations),
- and any court constructions.
None of these details can be extracted from the request as written, and the analysis cannot fabricate litigation events.
Which companies have challenged US7731930 via ANDA Paragraph IV certifications?
This requires Orange Book listing linkage plus Paragraph IV event data.
Were there settlements tied to US 7,713,930 that delayed generic launch?
Settlement terms are dataset-specific and require docket-level verification.
How does US 7,713,930 compare with other patents in the same technology area from the same assignee?
Comparison requires:
- identifying the assignee of US7731930,
- mapping their adjacent portfolios (both older and newer),
- and then determining whether later patents cover broader/closer-to-product claims.
No assignee or technology context is provided in the request.
What formulations or dosing methods are protected by US 7,713,930?
Protected subject matter can be:
- drug substance form (polymorph, salt, hydrate),
- finished dosage form (tablet, capsule, extended release, depot, implant),
- excipient system,
- coating composition and thickness,
- manufacturing steps and parameters,
- and dosing schedules or patient selection.
Without the patent claims/specification, the analysis cannot state which of these are protected.
What is the Orange Book status of US 7,713,930 and which NDA/ANDA listings include it?
Orange Book status is determined by whether US7731930 is:
- listed as an approved patent for a specific NDA product,
- listed for an ANDA reference listed drug,
- or listed for a specific strength and dosage form.
No NDA/ANDA mapping is included in the request, so Orange Book status cannot be accurately stated.
What biosimilar or biogeneric risk exists for the platform potentially covered by US 7,713,930?
Biosimilar risk depends on:
- whether US7731930 claims a biologic construct, formulation, or process,
- whether the biologic is under BLA/RLD exclusivity or patent exclusivity,
- and whether the claims are still enforceable.
Without the drug identity and claim type, no biosimilar risk can be provided.
Key Takeaways
- A claim-by-claim scope analysis of US Patent 7,713,930 requires the patent’s exact claim language and specification definitions; those are not present in the request.
- A verified family/continuation and forward/backward citation landscape requires bibliographic and citation datasets for US7731930; those are not present in the request.
- Expiration and PTA/PTE-adjusted term can’t be computed correctly without filing/adjustment/terminal disclaimer data for the specific patent.
- Litigation, Orange Book status, and Paragraph IV/settlement dynamics require product mapping and docket-level verification; none is provided.
FAQs
- How do I determine whether US 7,713,930 covers a formulation versus a method-of-use?
- What PT A adjustments can change the enforcement window for a US patent like 7,713,930?
- How does Orange Book patent listing affect whether a Paragraph IV challenge can assert US 7,713,930?
- What claim elements most often enable generic design-around when the patent involves process parameters?
- How do forward citations of US 7,713,930 help identify the most competitive follow-on patents?
References
- USPTO Patent Application Information Retrieval (PAIR) for US 7,713,930.
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
More… ↓
⤷ Start Trial
|
